Literature DB >> 15573917

Mutation of beta-catenin does not coexist with K-ras mutation in colorectal tumorigenesis.

Kazuhisa Shitoh1, Koji Koinuma, Taiji Furukawa, Masaki Okada, Hideo Nagai.   

Abstract

Alterations of the APC, K-ras, and beta-catenin genes are defined as early events in colorectal tumorigenesis. These alterations are well-known as constitutents of Vogelstein's pathway, however, the relationship among them is unclear. For understanding colorectal tumorigenesis it is important to evaluate their relationship. We analyzed the relationship between beta-catenin and K-ras gene mutations in clinical colorectal samples. Sixty-four cases of colorectal cancers (44 proximal, 20 distal) without a family history of colorectal cancer were used for this study. We purified genomic DNAs from fresh surgical samples and, thus, analyzed the mutations of beta-catenin (exon 3) and K-ras (codons 12 and 13) by PCR direct sequencing method using Big Dye terminator cycle sequencing with AmpliTaq polymerase FS. We found 27% (17/64) K-ras mutations (proximal 25%, 11/44; distal 30%, 6/20). The frequency of beta-catenin mutations was 11% (7/64; proximal 9%, 4/44; distal 15%, 3/20). All cases with beta-catenin mutation had no mutation of K-ras. All sites of beta-catenin mutation have been reported previously (codons 33, 34, 41, 45). In cell lines, it has been reported previously that beta-catenin and K-ras play the same roles in activation of cyclin D1 transcription. Our results may support this report and suggest that some colorectal cancers with beta-catenin mutation will progress without K-ras mutation. Further study may disclose a new pathway or new mechanism of colorectal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15573917     DOI: 10.1023/b:ddas.0000043376.41820.a6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

1.  Landscaping the cancer terrain.

Authors:  K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-05-15       Impact factor: 47.728

2.  Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin.

Authors:  S Ikeda; S Kishida; H Yamamoto; H Murai; S Koyama; A Kikuchi
Journal:  EMBO J       Date:  1998-03-02       Impact factor: 11.598

3.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

Authors:  O Tetsu; F McCormick
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

4.  Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors.

Authors:  M N Kitaeva; L Grogan; J P Williams; E Dimond; K Nakahara; P Hausner; J W DeNobile; P W Soballe; I R Kirsch
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

5.  Beta-catenin activation through mutation is rare in rectal cancer.

Authors:  M Nilbert; E Rambech
Journal:  Cancer Genet Cytogenet       Date:  2001-07-01

6.  Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.

Authors:  P J Morin; A B Sparks; V Korinek; N Barker; H Clevers; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

7.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.

Authors:  A B Sparks; P J Morin; B Vogelstein; K W Kinzler
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

8.  Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway.

Authors:  L Mirabelli-Primdahl; R Gryfe; H Kim; A Millar; C Luceri; D Dale; E Holowaty; B Bapat; S Gallinger; M Redston
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

9.  Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations.

Authors:  K Iwao; S Nakamori; M Kameyama; S Imaoka; M Kinoshita; T Fukui; S Ishiguro; Y Nakamura; Y Miyoshi
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

10.  Identification of c-MYC as a target of the APC pathway.

Authors:  T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1998-09-04       Impact factor: 47.728

View more
  4 in total

1.  Missense mutations in MLH1, MSH2, KRAS, and APC genes in colorectal cancer patients in Malaysia.

Authors:  Nor Azian Abdul Murad; Zulhabri Othman; Melati Khalid; Zuraini Abdul Razak; Rosniza Hussain; Sukumar Nadesan; Ismail Sagap; Isa Mohamed Rose; Wan Zurinah Wan Ngah; Rahman Jamal
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

2.  Mutations of beta-catenin and KRAS in colorectal carcinomas.

Authors:  Wael M Abdel-Rahman
Journal:  Dig Dis Sci       Date:  2006-03       Impact factor: 3.199

3.  Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.

Authors:  Tung-Cheng Chang; Yu-Tang Chin; André Wendindondé Nana; Shwu-Huey Wang; Yu-Min Liao; Yi-Ru Chen; Ya-Jung Shih; Chun A Changou; Yu-Chen Sh Yang; Kuan Wang; Jacqueline Whang-Peng; Liang-Shun Wang; Steven C Stain; Ai Shih; Hung-Yun Lin; Chih-Hsiung Wu; Paul J Davis
Journal:  Horm Cancer       Date:  2018-09-05       Impact factor: 3.869

Review 4.  Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers.

Authors:  Yu-Chen S H Yang; Po-Jui Ko; Yi-Shin Pan; Hung-Yun Lin; Jacqueline Whang-Peng; Paul J Davis; Kuan Wang
Journal:  J Biomed Sci       Date:  2021-04-08       Impact factor: 8.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.